Source: https://docplayer.net/11849737-Public-law-110-85-110th-congress-an-act.html
Timestamp: 2019-06-26 12:01:29
Document Index: 266615735

Matched Legal Cases: ['art 2', 'art 2', 'art 2', 'art 2', 'art 2', 'art 3']

Download "Public Law 110 85 110th Congress An Act"
Collin Jordan Reeves
1 PUBLIC LAW SEPT. 27, STAT. 823 Public Law th Congress An Act To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and for medical devices, to enhance the postmarket authorities of the Food and Drug Administration with respect to the safety of drugs, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the Food and Drug Administration Amendments Act of SEC. 2. TABLE OF CONTENTS. The table of contents for this Act is as follows: Sec. 1. Short title. Sec. 2. Table of contents. TITLE I PRESCRIPTION DRUG USER FEE AMENDMENTS OF 2007 Sec Short title; references in title; finding. Sec Definitions. Sec Authority to assess and use drug fees. Sec Fees relating to advisory review of prescription-drug television advertising. Sec Reauthorization; reporting requirements. Sec Sunset dates. Sec Effective date. Sec Savings clause. Sec Technical amendment; conforming amendment. TITLE II MEDICAL DEVICE USER FEE AMENDMENTS OF 2007 Sec Short title; references in title; finding. Subtitle A Fees Related to Medical Devices Sec Definitions. Sec Authority to assess and use device fees. Sec Reauthorization; reporting requirements. Sec Savings clause. Sec Additional authorization of appropriations for postmarket safety information. Sec Effective date. Sec Sunset clause. Subtitle B Amendments Regarding Regulation of Medical Devices Sec Extension of authority for third party review of premarket notification. Sec Registration. Sec Filing of lists of drugs and devices manufactured, prepared, propagated, and compounded by registrants; statements; accompanying disclosures. Sec Electronic registration and listing. Sec Report by Government Accountability Office. Sec Unique device identification system. Sec Frequency of reporting for certain devices. Sept. 27, 2007 [H.R. 3580] Food and Drug Administration Amendments Act of USC 301 note. VerDate Aug :45 Oct 12, 2007 Jkt PO Frm Fmt 6580 Sfmt 6582 E:\PUBLAW\PUBL APPS24 PsN: PUBL085
2 121 STAT. 824 PUBLIC LAW SEPT. 27, 2007 Sec Inspections by accredited persons. Sec Study of nosocomial infections relating to medical devices. Sec Report by the Food and Drug Administration regarding labeling information on the relationship between the use of indoor tanning devices and development of skin cancer or other skin damage. TITLE III PEDIATRIC MEDICAL DEVICE SAFETY AND IMPROVEMENT ACT OF 2007 Sec Short title. Sec Tracking pediatric device approvals. Sec Modification to humanitarian device exemption. Sec Encouraging pediatric medical device research. Sec Demonstration grants for improving pediatric device availability. Sec Amendments to office of pediatric therapeutics and pediatric advisory committee. Sec Postmarket surveillance. TITLE IV PEDIATRIC RESEARCH EQUITY ACT OF 2007 Sec Short title. Sec Reauthorization of Pediatric Research Equity Act. Sec Establishment of internal committee. Sec Government Accountability Office report. TITLE V BEST PHARMACEUTICALS FOR CHILDREN ACT OF 2007 Sec Short title. Sec Reauthorization of Best Pharmaceuticals for Children Act. Sec Training of pediatric pharmacologists. TITLE VI REAGAN-UDALL FOUNDATION Sec The Reagan-Udall Foundation for the Food and Drug Administration. Sec Office of the Chief Scientist. Sec Critical path public-private partnerships. TITLE VII CONFLICTS OF INTEREST Sec Conflicts of interest. TITLE VIII CLINICAL TRIAL DATABASES Sec Expanded clinical trial registry data bank. TITLE IX ENHANCED AUTHORITIES REGARDING POSTMARKET SAFETY OF DRUGS Subtitle A Postmarket Studies and Surveillance Sec Postmarket studies and clinical trials regarding human drugs; risk evaluation and mitigation strategies. Sec Enforcement. Sec No effect on withdrawal or suspension of approval. Sec Benefit-risk assessments. Sec Active postmarket risk identification and analysis. Sec Statement for inclusion in direct-to-consumer advertisements of drugs. Sec No effect on veterinary medicine. Sec Authorization of appropriations. Sec Effective date and applicability. Subtitle B Other Provisions to Ensure Drug Safety and Surveillance Sec Clinical trial guidance for antibiotic drugs. Sec Prohibition against food to which drugs or biological products have been added. Sec Assuring pharmaceutical safety. Sec Citizen petitions and petitions for stay of agency action. Sec Postmarket drug safety information for patients and providers. Sec Action package for approval. Sec Risk communication. Sec Referral to advisory committee. Sec Response to the institute of medicine. Sec Database for authorized generic drugs. Sec Adverse drug reaction reports and postmarket safety. TITLE X FOOD SAFETY Sec Findings. VerDate Aug :45 Oct 12, 2007 Jkt PO Frm Fmt 6580 Sfmt 6582 E:\PUBLAW\PUBL APPS24 PsN: PUBL085
3 PUBLIC LAW SEPT. 27, STAT. 825 Sec Ensuring the safety of pet food. Sec Ensuring efficient and effective communications during a recall. Sec State and Federal Cooperation. Sec Reportable Food Registry. Sec Enhanced aquaculture and seafood inspection. Sec Consultation regarding genetically engineered seafood products. Sec Sense of Congress. Sec Annual report to Congress. Sec Publication of annual reports. Sec Rule of construction. TITLE XI OTHER PROVISIONS Subtitle A In General Sec Policy on the review and clearance of scientific articles published by FDA employees. Sec Priority review to encourage treatments for tropical diseases. Sec Improving genetic test safety and quality. Sec NIH Technical amendments. Sec Severability clause. Subtitle B Antibiotic Access and Innovation Sec Identification of clinically susceptible concentrations of antimicrobials. Sec Orphan antibiotic drugs. Sec Exclusivity of certain drugs containing single enantiomers. Sec Report. TITLE I PRESCRIPTION DRUG USER FEE AMENDMENTS OF 2007 SEC SHORT TITLE; REFERENCES IN TITLE; FINDING. (a) SHORT TITLE. This title may be cited as the Prescription Drug User Fee Amendments of (b) REFERENCES IN TITLE. Except as otherwise specified, amendments made by this title to a section or other provision of law are amendments to such section or other provision of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.). (c) FINDING. The Congress finds that the fees authorized by the amendments made in this title will be dedicated toward expediting the drug development process and the process for the review of human drug applications, including postmarket drug safety activities, as set forth in the goals identified for purposes of part 2 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act, in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate and the Chairman of the Committee on Energy and Commerce of the House of Representatives, as set forth in the Congressional Record. SEC DEFINITIONS. Section 735 (21 U.S.C. 379g) is amended (1) in the matter before paragraph (1), by striking For purposes of this subchapter and inserting For purposes of this part ; (2) in paragraph (1) (A) in subparagraph (A), by striking 505(b)(1), and inserting 505(b), or ; (B) by striking subparagraph (B); (C) by redesignating subparagraph (C) as subparagraph (B); and Prescription Drug User Fee Amendments of USC 301 note. 21 USC 379g note. VerDate Aug :49 Oct 12, 2007 Jkt PO Frm Fmt 6580 Sfmt 6581 E:\PUBLAW\PUBL APPS24 PsN: PUBL085
4 121 STAT. 826 PUBLIC LAW SEPT. 27, 2007 (D) in the matter following subparagraph (B), as so redesignated, by striking subparagraph (C) and inserting subparagraph (B) ; (3) in paragraph (3)(C) (A) by striking 505(j)(7)(A) and inserting 505(j)(7)(A) (not including the discontinued section of such list) ; and (B) by inserting before the period (not including the discontinued section of such list) ; (4) in paragraph (4), by inserting before the period at the end the following: (such as capsules, tablets, or lyophilized products before reconstitution) ; (5) by amending paragraph (6)(F) to read as follows: (F) Postmarket safety activities with respect to drugs approved under human drug applications or supplements, including the following activities: (i) Collecting, developing, and reviewing safety information on approved drugs, including adverse event reports. (ii) Developing and using improved adverse-event data-collection systems, including information technology systems. (iii) Developing and using improved analytical tools to assess potential safety problems, including access to external data bases. (iv) Implementing and enforcing section 505(o) (relating to postapproval studies and clinical trials and labeling changes) and section 505(p) (relating to risk evaluation and mitigation strategies). (v) Carrying out section 505(k)(5) (relating to adverse event reports and postmarket safety activities). ; (6) in paragraph (8) (A) by striking April of the preceding fiscal year and inserting October of the preceding fiscal year ; and (B) by striking April 1997 and inserting October 1996 ; (7) by redesignating paragraph (9) as paragraph (11); and (8) by inserting after paragraph (8) the following paragraphs: (9) The term person includes an affiliate thereof. (10) The term active, with respect to a commercial investigational new drug application, means such an application to which information was submitted during the relevant period.. SEC AUTHORITY TO ASSESS AND USE DRUG FEES. (a) TYPES OF FEES. Section 736(a) (21 U.S.C. 379h(a)) is amended (1) in the matter preceding paragraph (1), by striking 2003 and inserting 2008 ; (2) in paragraph (1) (A) in subparagraph (D) (i) in the heading, by inserting OR WITHDRAWN BEFORE FILING after REFUSED FOR FILING ; and (ii) by inserting before the period at the end the following: or withdrawn without a waiver before filing ; VerDate Aug :49 Oct 12, 2007 Jkt PO Frm Fmt 6580 Sfmt 6581 E:\PUBLAW\PUBL APPS24 PsN: PUBL085
5 PUBLIC LAW SEPT. 27, STAT. 827 (B) by redesignating subparagraphs (E) and (F) as subparagraphs (F) and (G), respectively; and (C) by inserting after subparagraph (D) the following: (E) FEES FOR APPLICATIONS PREVIOUSLY REFUSED FOR FILING OR WITHDRAWN BEFORE FILING. A human drug application or supplement that was submitted but was refused for filing, or was withdrawn before being accepted or refused for filing, shall be subject to the full fee under subparagraph (A) upon being resubmitted or filed over protest, unless the fee is waived or reduced under subsection (d). ; and (3) in paragraph (2) (A) in subparagraph (A), by striking subparagraph (B) and inserting subparagraphs (B) and (C) ; and (B) by adding at the end the following: (C) SPECIAL RULES FOR POSITRON EMISSION TOMOG- RAPHY DRUGS. (i) IN GENERAL. Except as provided in clause (ii), each person who is named as the applicant in an approved human drug application for a positron emission tomography drug shall be subject under subparagraph (A) to one-sixth of an annual establishment fee with respect to each such establishment identified in the application as producing positron emission tomography drugs under the approved application. (ii) EXCEPTION FROM ANNUAL ESTABLISHMENT FEE. Each person who is named as the applicant in an application described in clause (i) shall not be assessed an annual establishment fee for a fiscal year if the person certifies to the Secretary, at a time specified by the Secretary and using procedures specified by the Secretary, that (I) the person is a not-for-profit medical center that has only 1 establishment for the production of positron emission tomography drugs; and (II) at least 95 percent of the total number of doses of each positron emission tomography drug produced by such establishment during such fiscal year will be used within the medical center. (iii) DEFINITION. For purposes of this subparagraph, the term positron emission tomography drug has the meaning given to the term compounded positron emission tomography drug in section 201(ii), except that paragraph (1)(B) of such section shall not apply.. (b) FEE REVENUE AMOUNTS. Section 736(b) (21 U.S.C. 379h(b)) is amended to read as follows: (b) FEE REVENUE AMOUNTS. (1) IN GENERAL. For each of the fiscal years 2008 through 2012, fees under subsection (a) shall, except as provided in subsections (c), (d), (f), and (g), be established to generate a total revenue amount under such subsection that is equal to the sum of (A) $392,783,000; and VerDate Aug :49 Oct 12, 2007 Jkt PO Frm Fmt 6580 Sfmt 6581 E:\PUBLAW\PUBL APPS24 PsN: PUBL085
6 121 STAT. 828 PUBLIC LAW SEPT. 27, 2007 Applicability. (B) an amount equal to the modified workload adjustment factor for fiscal year 2007 (as determined under paragraph (3)). (2) TYPES OF FEES. Of the total revenue amount determined for a fiscal year under paragraph (1) (A) one-third shall be derived from fees under subsection (a)(1) (relating to human drug applications and supplements); (B) one-third shall be derived from fees under subsection (a)(2) (relating to prescription drug establishments); and (C) one-third shall be derived from fees under subsection (a)(3) (relating to prescription drug products). (3) MODIFIED WORKLOAD ADJUSTMENT FACTOR FOR FISCAL YEAR For purposes of paragraph (1)(B), the Secretary shall determine the modified workload adjustment factor by determining the dollar amount that results from applying the methodology that was in effect under subsection (c)(2) for fiscal year 2007 to the amount $354,893,000, except that, with respect to the portion of such determination that is based on the change in the total number of commercial investigational new drug applications, the Secretary shall count the number of such applications that were active during the most recent 12- month period for which data on such submissions is available. (4) ADDITIONAL FEE REVENUES FOR DRUG SAFETY. (A) IN GENERAL. For each of the fiscal years 2008 through 2012, paragraph (1)(A) shall be applied by substituting the amount determined under subparagraph (B) for $392,783,000. (B) AMOUNT DETERMINED. For each of the fiscal years 2008 through 2012, the amount determined under this subparagraph is the sum of (i) $392,783,000; plus (ii)(i) for fiscal year 2008, $25,000,000; (II) for fiscal year 2009, $35,000,000; (III) for fiscal year 2010, $45,000,000; (IV) for fiscal year 2011, $55,000,000; and (V) for fiscal year 2012, $65,000,000.. (c) ADJUSTMENTS TO FEES. (1) INFLATION ADJUSTMENT. Section 736(c)(1) (21 U.S.C. 379h(c)(1)) is amended (A) in the matter preceding subparagraph (A), by striking The revenues established in subsection (b) and inserting For fiscal year 2009 and subsequent fiscal years, the revenues established in subsection (b) ; (B) in subparagraph (A), by striking or at the end; (C) in subparagraph (B), by striking the period at the end and inserting, or ; (D) by inserting after subparagraph (B) the following: (C) the average annual change in the cost, per fulltime equivalent position of the Food and Drug Administration, of all personnel compensation and benefits paid with respect to such positions for the first 5 years of the preceding 6 fiscal years. ; and (E) in the matter following subparagraph (C) (as added by subparagraph (D)), by striking fiscal year 2003 and inserting fiscal year VerDate Aug :49 Oct 12, 2007 Jkt PO Frm Fmt 6580 Sfmt 6581 E:\PUBLAW\PUBL APPS24 PsN: PUBL085
7 PUBLIC LAW SEPT. 27, STAT. 829 (2) WORKLOAD ADJUSTMENT. Section 736(c)(2) (21 U.S.C. 379h(c)(2)) is amended (A) in the matter preceding subparagraph (A), by striking Beginning with fiscal year 2004, and inserting For fiscal year 2009 and subsequent fiscal years, ; (B) in subparagraph (A), in the first sentence (i) by striking human drug applications, and inserting human drug applications (adjusted for changes in review activities, as described in the notice that the Secretary is required to publish in the Federal Register under this subparagraph), ; (ii) by striking commercial investigational new drug applications, ; and (iii) by inserting before the period the following:, and the change in the total number of active commercial investigational new drug applications (adjusted for changes in review activities, as so described) during the most recent 12-month period for which data on such submissions is available ; (C) in subparagraph (B), by adding at the end the following: Any adjustment for changes in review activities made in setting fees and revenue amounts for fiscal year 2009 may not result in the total workload adjustment being more than 2 percentage points higher than it would have been in the absence of the adjustment for changes in review activities. ; and (D) by adding at the end the following: (C) The Secretary shall contract with an independent accounting firm to study the adjustment for changes in review activities applied in setting fees and revenue amounts for fiscal year 2009 and to make recommendations, if warranted, for future changes in the methodology for calculating the adjustment. After review of the recommendations, the Secretary shall, if warranted, make appropriate changes to the methodology, and the changes shall be effective for each of the fiscal years 2010 through The Secretary shall not make any adjustment for changes in review activities for any fiscal year after 2009 unless such study has been completed.. (3) RENT AND RENT-RELATED COST ADJUSTMENT. Section 736(c) (21 U.S.C. 379h(c)) is amended (A) by redesignating paragraphs (3), (4), and (5) as paragraphs (4), (5), and (6), respectively; and (B) by inserting after paragraph (2) the following: (3) RENT AND RENT-RELATED COST ADJUSTMENT. For fiscal year 2010 and each subsequent fiscal year, the Secretary shall, before making adjustments under paragraphs (1) and (2), decrease the fee revenue amount established in subsection (b) if actual costs paid for rent and rent-related expenses for the preceding fiscal year are less than estimates made for such year in fiscal year Any reduction made under this paragraph shall not exceed the amount by which such costs fall below the estimates made in fiscal year 2006 for such fiscal year, and shall not exceed $11,721,000 for any fiscal year.. (4) FINAL YEAR ADJUSTMENT. Paragraph (4) of section 736(c) (21 U.S.C. 379h(c)), as redesignated by paragraph (3)(A), is amended to read as follows: Contracts. Study. Effective date. VerDate Aug :49 Oct 12, 2007 Jkt PO Frm Fmt 6580 Sfmt 6581 E:\PUBLAW\PUBL APPS24 PsN: PUBL085
8 121 STAT. 830 PUBLIC LAW SEPT. 27, 2007 (4) FINAL YEAR ADJUSTMENT. (A) INCREASE IN FEES. For fiscal year 2012, the Secretary may, in addition to adjustments under this paragraph and paragraphs (1), (2), and (3), further increase the fee revenues and fees established in subsection (b) if such an adjustment is necessary to provide for not more than 3 months of operating reserves of carryover user fees for the process for the review of human drug applications for the first 3 months of fiscal year If such an adjustment is necessary, the rationale for the amount of the increase shall be contained in the annual notice establishing fee revenues and fees for fiscal year If the Secretary has carryover balances for such process in excess of 3 months of such operating reserves, the adjustment under this subparagraph shall not be made. (B) DECREASE IN FEES. (i) IN GENERAL. For fiscal year 2012, the Secretary may, in addition to adjustments under this paragraph and paragraphs (1), (2), and (3), decrease the fee revenues and fees established in subsection (b) by the amount determined in clause (ii), if, for fiscal year 2009 or 2010 (I) the amount of the total appropriations for the Food and Drug Administration for such fiscal year (excluding the amount of fees appropriated for such fiscal year) exceeds the amount of the total appropriations for the Food and Drug Administration for fiscal year 2008 (excluding the amount of fees appropriated for such fiscal year), adjusted as provided under paragraph (1); and (II) the amount of the total appropriations expended for the process for the review of human drug applications at the Food and Drug Administration for such fiscal year (excluding the amount of fees appropriated for such fiscal year) exceeds the amount of appropriations expended for the process for the review of human drug applications at the Food and Drug Administration for fiscal year 2008 (excluding the amount of fees appropriated for such fiscal year), adjusted as provided under paragraph (1). (ii) AMOUNT OF DECREASE. The amount determined in this clause is the lesser of (I) the amount equal to the sum of the amounts that, for each of fiscal years 2009 and 2010, is the lesser of (aa) the excess amount described in clause (i)(ii) for such fiscal year; or (bb) the amount specified in subsection (b)(4)(b)(ii) for such fiscal year; or (II) $65,000,000. (iii) LIMITATIONS. (I) FISCAL YEAR CONDITION. In making the determination under clause (ii), an amount described in subclause (I) of such clause for fiscal year 2009 or 2010 shall be taken into account VerDate Aug :49 Oct 12, 2007 Jkt PO Frm Fmt 6580 Sfmt 6581 E:\PUBLAW\PUBL APPS24 PsN: PUBL085
9 PUBLIC LAW SEPT. 27, STAT. 831 only if subclauses (I) and (II) of clause (i) apply to such fiscal year. (II) RELATION TO SUBPARAGRAPH (A). The Secretary shall limit any decrease under this paragraph if such a limitation is necessary to provide for the 3 months of operating reserves described in subparagraph (A).. (5) LIMIT. Paragraph (5) of section 736(c) (21 U.S.C. 379h(c)), as redesignated by paragraph (3)(A), is amended by striking 2002 and inserting (d) FEE WAIVER OR REDUCTION. Section 736(d) (21 U.S.C. 379h(d)) is amended (1) in paragraph (1), in the matter preceding subparagraph (A) (A) by inserting after The Secretary shall grant the following: to a person who is named as the applicant in a human drug application ; and (B) by inserting to that person after one or more fees assessed ; (2) by redesignating paragraphs (2) and (3) as paragraphs (3) and (4), respectively; (3) by inserting after paragraph (1) the following: (2) CONSIDERATIONS. In determining whether to grant a waiver or reduction of a fee under paragraph (1), the Secretary shall consider only the circumstances and assets of the applicant involved and any affiliate of the applicant. ; and (4) in paragraph (4) (as redesignated by paragraph (2)), in subparagraph (A), by inserting before the period the following:, and that does not have a drug product that has been approved under a human drug application and introduced or delivered for introduction into interstate commerce. (e) CREDITING AND AVAILABILITY OF FEES. (1) AUTHORIZATION OF APPROPRIATIONS. Section 736(g)(3) (21 U.S.C. 379h(g)(3)) is amended to read as follows: (3) AUTHORIZATION OF APPROPRIATIONS. For each of the fiscal years 2008 through 2012, there is authorized to be appropriated for fees under this section an amount equal to the total revenue amount determined under subsection (b) for the fiscal year, as adjusted or otherwise affected under subsection (c) and paragraph (4) of this subsection.. (2) OFFSET. Section 736(g)(4) (21 U.S.C. 379h(g)(4)) is amended to read as follows: (4) OFFSET. If the sum of the cumulative amount of fees collected under this section for the fiscal years 2008 through 2010 and the amount of fees estimated to be collected under this section for fiscal year 2011 exceeds the cumulative amount appropriated under paragraph (3) for the fiscal years 2008 through 2011, the excess shall be credited to the appropriation account of the Food and Drug Administration as provided in paragraph (1), and shall be subtracted from the amount of fees that would otherwise be authorized to be collected under this section pursuant to appropriation Acts for fiscal year (f) EXEMPTION FOR ORPHAN DRUGS. Section 736 (21 U.S.C. 379h) is further amended by adding at the end the following: (k) ORPHAN DRUGS. VerDate Aug :49 Oct 12, 2007 Jkt PO Frm Fmt 6580 Sfmt 6581 E:\PUBLAW\PUBL APPS24 PsN: PUBL085
10 121 STAT. 832 PUBLIC LAW SEPT. 27, USC 379h note. 21 USC 379h 1. Effective date. Deadlines. Federal Register, publication. (1) EXEMPTION. A drug designated under section 526 for a rare disease or condition and approved under section 505 or under section 351 of the Public Health Service Act shall be exempt from product and establishment fees under this section, if the drug meets all of the following conditions: (A) The drug meets the public health requirements contained in this Act as such requirements are applied to requests for waivers for product and establishment fees. (B) The drug is owned or licensed and is marketed by a company that had less than $50,000,000 in gross worldwide revenue during the previous year. (2) EVIDENCE OF QUALIFICATION. An exemption under paragraph (1) applies with respect to a drug only if the applicant involved submits a certification that its gross annual revenues did not exceed $50,000,000 for the preceding 12 months before the exemption was requested.. (g) CONFORMING AMENDMENT. Section 736(a) (21 U.S.C. 379h(a)) is amended in paragraphs (1)(A)(i), (1)(A)(ii), (2)(A), and (3)(A) by striking (c)(4) each place such term appears and inserting (c)(5). (h) TECHNICAL AMENDMENT. (1) AMENDMENT. Section 736(g)(1) (21 U.S.C. 379h(g)(1)) is amended by striking the first sentence and inserting the following: Fees authorized under subsection (a) shall be collected and available for obligation only to the extent and in the amount provided in advance in appropriations Acts. Such fees are authorized to remain available until expended.. (2) EFFECTIVE DATE. Paragraph (1) shall take effect as if included in section 504 of the Prescription Drug User Fee Amendments of 2002 (Public Law ; 116 Stat. 687). SEC FEES RELATING TO ADVISORY REVIEW OF PRESCRIPTION- DRUG TELEVISION ADVERTISING. Part 2 of subchapter C of chapter VII (21 U.S.C. 379g et seq.) is amended by adding after section 736 the following: SEC. 736A. FEES RELATING TO ADVISORY REVIEW OF PRESCRIPTION- DRUG TELEVISION ADVERTISING. (a) TYPES OF DIRECT-TO-CONSUMER TELEVISION ADVERTISE- MENT REVIEW FEES. Beginning in fiscal year 2008, the Secretary shall assess and collect fees in accordance with this section as follows: (1) ADVISORY REVIEW FEE. (A) IN GENERAL. With respect to a proposed directto-consumer television advertisement (referred to in this section as a DTC advertisement ), each person that on or after October 1, 2007, submits such an advertisement for advisory review by the Secretary prior to its initial public dissemination shall, except as provided in subparagraph (B), be subject to a fee established under subsection (c)(3). (B) EXCEPTION FOR REQUIRED SUBMISSIONS. A DTC advertisement that is required to be submitted to the Secretary prior to initial public dissemination is not subject to a fee under subparagraph (A) unless the sponsor designates the submission as a submission for advisory review. (C) NOTICE TO SECRETARY OF NUMBER OF ADVERTISEMENTS. Not later than June 1 of each fiscal VerDate Aug :45 Oct 12, 2007 Jkt PO Frm Fmt 6580 Sfmt 6581 E:\PUBLAW\PUBL APPS24 PsN: PUBL085
11 PUBLIC LAW SEPT. 27, STAT. 833 year, the Secretary shall publish a notice in the Federal Register requesting any person to notify the Secretary within 30 days of the number of DTC advertisements the person intends to submit for advisory review in the next fiscal year. Notwithstanding the preceding sentence, for fiscal year 2008, the Secretary shall publish such a notice in the Federal Register not later than 30 days after the date of the enactment of the Food and Drug Administration Amendments Act of (D) PAYMENT. (i) IN GENERAL. The fee required by subparagraph (A) (referred to in this section as an advisory review fee ) shall be due not later than October 1 of the fiscal year in which the DTC advertisement involved is intended to be submitted for advisory review, subject to subparagraph (F)(i). Notwithstanding the preceding sentence, the advisory review fee for any DTC advertisement that is intended to be submitted for advisory review during fiscal year 2008 shall be due not later than 120 days after the date of the enactment of the Food and Drug Administration Amendments of 2007 or an earlier date as specified by the Secretary. (ii) EFFECT OF SUBMISSION. Notification of the Secretary under subparagraph (C) of the number of DTC advertisements a person intends to submit for advisory review is a legally binding commitment by that person to pay the annual advisory review fee for that number of submissions on or before October 1 of the fiscal year in which the advertisement is intended to be submitted. Notwithstanding the preceding sentence, the commitment shall be a legally binding commitment by that person to pay the annual advisory review fee for that number of submissions for fiscal year 2008 by the date specified in clause (i). (iii) NOTICE REGARDING CARRYOVER SUBMIS- SIONS. In making a notification under subparagraph (C), the person involved shall in addition notify the Secretary if under subparagraph (F)(i) the person intends to submit a DTC advertisement for which the advisory review fee has already been paid. If the person does not so notify the Secretary, each DTC advertisement submitted by the person for advisory review in the fiscal year involved shall be subject to the advisory review fee. (E) MODIFICATION OF ADVISORY REVIEW FEE. (i) LATE PAYMENT. If a person has submitted a notification under subparagraph (C) with respect to a fiscal year and has not paid all advisory review fees due under subparagraph (D) not later than November 1 of such fiscal year (or, in the case of such a notification submitted with respect to fiscal year 2008, not later than 150 days after the date of the enactment of the Food and Drug Administration Amendments Act of 2007 or an earlier date specified by the Secretary), the fees shall be regarded as late Deadlines. Applicability. VerDate Aug :49 Oct 12, 2007 Jkt PO Frm Fmt 6580 Sfmt 6581 E:\PUBLAW\PUBL APPS24 PsN: PUBL085
12 121 STAT. 834 PUBLIC LAW SEPT. 27, 2007 Deadlines. and an increase in the amount of fees applies in accordance with this clause, notwithstanding any other provision of this section. For such person, all advisory review fees for such fiscal year shall be due and payable 20 days before any direct-to-consumer advertisement is submitted to the Secretary for advisory review, and each such fee shall be equal to 150 percent of the fee that otherwise would have applied pursuant to subsection (c)(3). (ii) EXCEEDING IDENTIFIED NUMBER OF SUBMIS- SIONS. If a person submits a number of DTC advertisements for advisory review in a fiscal year that exceeds the number identified by the person under subparagraph (C), an increase in the amount of fees applies under this clause for each submission in excess of such number, notwithstanding any other provision of this section. For each such DTC advertisement, the advisory review fee shall be due and payable 20 days before the advertisement is submitted to the Secretary, and the fee shall be equal to 150 percent of the fee that otherwise would have applied pursuant to subsection (c)(3). (F) LIMITS. (i) SUBMISSIONS. For each advisory review fee paid by a person for a fiscal year, the person is entitled to acceptance for advisory review by the Secretary of one DTC advertisement and acceptance of one resubmission for advisory review of the same advertisement. The advertisement shall be submitted for review in the fiscal year for which the fee was assessed, except that a person may carry over not more than one paid advisory review submission to the next fiscal year. Resubmissions may be submitted without regard to the fiscal year of the initial advisory review submission. (ii) NO REFUNDS. Except as provided by subsections (d)(4) and (f), fees paid under this section shall not be refunded. (iii) NO WAIVERS, EXEMPTIONS, OR REDUCTIONS. The Secretary shall not grant a waiver, exemption, or reduction of any fees due or payable under this section. (iv) RIGHT TO ADVISORY REVIEW NOT TRANSFER- ABLE. The right to an advisory review under this paragraph is not transferable, except to a successor in interest. (2) OPERATING RESERVE FEE. (A) IN GENERAL. Each person that on or after October 1, 2007, is assessed an advisory review fee under paragraph (1) shall be subject to fee established under subsection (d)(2) (referred to in this section as an operating reserve fee ) for the first fiscal year in which an advisory review fee is assessed to such person. The person is not subject to an operating reserve fee for any other fiscal year. (B) PAYMENT. Except as provided in subparagraph (C), the operating reserve fee shall be due no later than VerDate Aug :49 Oct 12, 2007 Jkt PO Frm Fmt 6580 Sfmt 6581 E:\PUBLAW\PUBL APPS24 PsN: PUBL085
13 PUBLIC LAW SEPT. 27, STAT. 835 (i) October 1 of the first fiscal year in which the person is required to pay an advisory review fee under paragraph (1); or (ii) for fiscal year 2008, 120 days after the date of the enactment of the Food and Drug Administration Amendments Act of 2007 or an earlier date specified by the Secretary. (C) LATE NOTICE OF SUBMISSION. If, in the first fiscal year of a person s participation in the program under this section, that person submits any DTC advertisements for advisory review that are in excess of the number identified by that person in response to the Federal Register notice described in subsection (a)(1)(c), that person shall pay an operating reserve fee for each of those advisory reviews equal to the advisory review fee for each submission established under paragraph (1)(E)(ii). Fees required by this subparagraph shall be in addition to any fees required by subparagraph (A). Fees under this subparagraph shall be due 20 days before any DTC advertisement is submitted by such person to the Secretary for advisory review. (D) LATE PAYMENT. (i) IN GENERAL. Notwithstanding subparagraph (B), and subject to clause (ii), an operating reserve fee shall be regarded as late if the person required to pay the fee has not paid the complete operating reserve fee by (I) for fiscal year 2008, 150 days after the date of the enactment of the Food and Drug Administration Amendments Act of 2007 or an earlier date specified by the Secretary; or (II) in any subsequent year, November 1. (ii) COMPLETE PAYMENT. The complete operating reserve fee shall be due and payable 20 days before any DTC advertisement is submitted by such person to the Secretary for advisory review. (iii) AMOUNT. Notwithstanding any other provision of this section, an operating reserve fee that is regarded as late under this subparagraph shall be equal to 150 percent of the operating reserve fee that otherwise would have applied pursuant to subsection (d). (b) ADVISORY REVIEW FEE REVENUE AMOUNTS. Fees under subsection (a)(1) shall be established to generate revenue amounts of $6,250,000 for each of fiscal years 2008 through 2012, as adjusted pursuant to subsections (c) and (g)(4). (c) ADJUSTMENTS. (1) INFLATION ADJUSTMENT. Beginning with fiscal year 2009, the revenues established in subsection (b) shall be adjusted by the Secretary by notice, published in the Federal Register, for a fiscal year to reflect the greater of (A) the total percentage change that occurred in the Consumer Price Index for all urban consumers (all items; U.S. city average), for the 12-month period ending June 30 preceding the fiscal year for which fees are being established; (B) the total percentage change for the previous fiscal year in basic pay under the General Schedule in accordance Deadlines. Effective date. Notice. Federal Register, publication. VerDate Aug :49 Oct 12, 2007 Jkt PO Frm Fmt 6580 Sfmt 6581 E:\PUBLAW\PUBL APPS24 PsN: PUBL085
14 121 STAT. 836 PUBLIC LAW SEPT. 27, 2007 Effective date. Federal Register, publication. Deadlines. with section 5332 of title 5, United States Code, as adjusted by any locality-based comparability payment pursuant to section 5304 of such title for Federal employees stationed in the District of Columbia; or (C) the average annual change in the cost, per fulltime equivalent position of the Food and Drug Administration, of all personnel compensation and benefits paid with respect to such positions for the first 5 fiscal years of the previous 6 fiscal years. The adjustment made each fiscal year by this subsection shall be added on a compounded basis to the sum of all adjustments made each fiscal year after fiscal year 2008 under this subsection. (2) WORKLOAD ADJUSTMENT. Beginning with fiscal year 2009, after the fee revenues established in subsection (b) are adjusted for a fiscal year for inflation in accordance with paragraph (1), the fee revenues shall be adjusted further for such fiscal year to reflect changes in the workload of the Secretary with respect to the submission of DTC advertisements for advisory review prior to initial dissemination. With respect to such adjustment: (A) The adjustment shall be determined by the Secretary based upon the number of DTC advertisements identified pursuant to subsection (a)(1)(c) for the upcoming fiscal year, excluding allowable previously paid carry over submissions. The adjustment shall be determined by multiplying the number of such advertisements projected for that fiscal year that exceeds 150 by $27,600 (adjusted each year beginning with fiscal year 2009 for inflation in accordance with paragraph (1)). The Secretary shall publish in the Federal Register the fee revenues and fees resulting from the adjustment and the supporting methodologies. (B) Under no circumstances shall the adjustment result in fee revenues for a fiscal year that are less than the fee revenues established for the prior fiscal year. (3) ANNUAL FEE SETTING FOR ADVISORY REVIEW. (A) IN GENERAL. Not later than August 1 of each fiscal year (or, with respect to fiscal year 2008, not later than 90 days after the date of the enactment of the Food and Drug Administration Amendments Act of 2007), the Secretary shall establish for the next fiscal year the DTC advertisement advisory review fee under subsection (a)(1), based on the revenue amounts established under subsection (b), the adjustments provided under paragraphs (1) and (2), and the number of DTC advertisements identified pursuant to subsection (a)(1)(c), excluding allowable previously-paid carry over submissions. The annual advisory review fee shall be established by dividing the fee revenue for a fiscal year (as adjusted pursuant to this subsection) by the number of DTC advertisements so identified, excluding allowable previously-paid carry over submissions under subsection (a)(1)(f)(i). (B) FISCAL YEAR 2008 FEE LIMIT. Notwithstanding subsection (b) and the adjustments pursuant to this subsection, the fee established under subparagraph (A) for VerDate Aug :49 Oct 12, 2007 Jkt PO Frm Fmt 6580 Sfmt 6581 E:\PUBLAW\PUBL APPS24 PsN: PUBL085
15 PUBLIC LAW SEPT. 27, STAT. 837 fiscal year 2008 may not be more than $83,000 per submission for advisory review. (C) ANNUAL FEE LIMIT. Notwithstanding subsection (b) and the adjustments pursuant to this subsection, the fee established under subparagraph (A) for a fiscal year after fiscal year 2008 may not be more than 50 percent more than the fee established for the prior fiscal year. (D) LIMIT. The total amount of fees obligated for a fiscal year may not exceed the total costs for such fiscal year for the resources allocated for the process for the advisory review of prescription drug advertising. (d) OPERATING RESERVES. (1) IN GENERAL. The Secretary shall establish in the Food and Drug Administration salaries and expenses appropriation account without fiscal year limitation a Direct-to-Consumer Advisory Review Operating Reserve, of at least $6,250,000 in fiscal year 2008, to continue the program under this section in the event the fees collected in any subsequent fiscal year pursuant to subsection (a)(1) do not generate the fee revenue amount established for that fiscal year. (2) FEE SETTING. The Secretary shall establish the operating reserve fee under subsection (a)(2)(a) for each person required to pay the fee by multiplying the number of DTC advertisements identified by that person pursuant to subsection (a)(1)(c) by the advisory review fee established pursuant to subsection (c)(3) for that fiscal year, except that in no case shall the operating reserve fee assessed be less than the operating reserve fee assessed if the person had first participated in the program under this section in fiscal year (3) USE OF OPERATING RESERVE. The Secretary may use funds from the reserves only to the extent necessary in any fiscal year to make up the difference between the fee revenue amount established for that fiscal year under subsections (b) and (c) and the amount of fees actually collected for that fiscal year pursuant to subsection (a)(1), or to pay costs of ending the program under this section if it is terminated pursuant to subsection (f) or not reauthorized beyond fiscal year (4) REFUND OF OPERATING RESERVES. Within 120 days after the end of fiscal year 2012, or if the program under this section ends early pursuant to subsection (f), the Secretary, after setting aside sufficient operating reserve amounts to terminate the program under this section, shall refund all amounts remaining in the operating reserve on a pro rata basis to each person that paid an operating reserve fee assessment. In no event shall the refund to any person exceed the total amount of operating reserve fees paid by such person pursuant to subsection (a)(2). (e) EFFECT OF FAILURE TO PAY FEES. Notwithstanding any other requirement, a submission for advisory review of a DTC advertisement submitted by a person subject to fees under subsection (a) shall be considered incomplete and shall not be accepted for review by the Secretary until all fees owed by such person under this section have been paid. (f) EFFECT OF INADEQUATE FUNDING OF PROGRAM. (1) INITIAL FUNDING. If on November 1, 2007, or 120 days after the date of the enactment of the Food and Drug Administration Amendments Act of 2007, whichever is later, Effective date. VerDate Aug :49 Oct 12, 2007 Jkt PO Frm Fmt 6580 Sfmt 6581 E:\PUBLAW\PUBL APPS24 PsN: PUBL085
16 121 STAT. 838 PUBLIC LAW SEPT. 27, 2007 Effective date. Notification. the Secretary has not received at least $11,250,000 in advisory review fees and operating reserve fees combined, the program under this section shall not commence and all collected fees shall be refunded. (2) LATER FISCAL YEARS. Beginning in fiscal year 2009, if, on November 1 of the fiscal year, the combination of the operating reserves, annual fee revenues from that fiscal year, and unobligated fee revenues from prior fiscal years falls below $9,000,000, adjusted for inflation (as described in subsection (c)(1)), the program under this section shall terminate, and the Secretary shall notify all participants, retain any money from the unused advisory review fees and the operating reserves needed to terminate the program, and refund the remainder of the unused fees and operating reserves. To the extent required to terminate the program, the Secretary shall first use unobligated advisory review fee revenues from prior fiscal years, then the operating reserves, and finally, unused advisory review fees from the relevant fiscal year. (g) CREDITING AND AVAILABILITY OF FEES. (1) IN GENERAL. Fees authorized under subsection (a) shall be collected and available for obligation only to the extent and in the amount provided in advance in appropriations Acts. Such fees are authorized to remain available until expended. Such sums as may be necessary may be transferred from the Food and Drug Administration salaries and expenses appropriation account without fiscal year limitation to such appropriation account for salaries and expenses with such fiscal year limitation. The sums transferred shall be available solely for the process for the advisory review of prescription drug advertising. (2) COLLECTIONS AND APPROPRIATION ACTS. (A) IN GENERAL. The fees authorized by this section (i) shall be retained in each fiscal year in an amount not to exceed the amount specified in appropriation Acts, or otherwise made available for obligation for such fiscal year; and (ii) shall be available for obligation only if the amounts appropriated as budget authority for such fiscal year are sufficient to support a number of fulltime equivalent review employees that is not fewer than the number of such employees supported in fiscal year (B) REVIEW EMPLOYEES. For purposes of subparagraph (A)(ii), the term full-time equivalent review employees means the total combined number of full-time equivalent employees in (i) the Center for Drug Evaluation and Research, Division of Drug Marketing, Advertising, and Communications, Food and Drug Administration; and (ii) the Center for Biologics Evaluation and Research, Advertising and Promotional Labeling Branch, Food and Drug Administration. (3) AUTHORIZATION OF APPROPRIATIONS. For each of the fiscal years 2008 through 2012, there is authorized to be appropriated for fees under this section an amount equal to the total revenue amount determined under subsection (b) for the VerDate Aug :49 Oct 12, 2007 Jkt PO Frm Fmt 6580 Sfmt 6581 E:\PUBLAW\PUBL APPS24 PsN: PUBL085
17 PUBLIC LAW SEPT. 27, STAT. 839 fiscal year, as adjusted pursuant to subsection (c) and paragraph (4) of this subsection, plus amounts collected for the reserve fund under subsection (d). (4) OFFSET. Any amount of fees collected for a fiscal year under this section that exceeds the amount of fees specified in appropriation Acts for such fiscal year shall be credited to the appropriation account of the Food and Drug Administration as provided in paragraph (1), and shall be subtracted from the amount of fees that would otherwise be collected under this section pursuant to appropriation Acts for a subsequent fiscal year. (h) DEFINITIONS. For purposes of this section: (1) The term advisory review means reviewing and providing advisory comments on DTC advertisements regarding compliance of a proposed advertisement with the requirements of this Act prior to its initial public dissemination. (2) The term advisory review fee has the meaning indicated for such term in subsection (a)(1)(d). (3) The term carry over submission means a submission for an advisory review for which a fee was paid in one fiscal year that is submitted for review in the following fiscal year. (4) The term direct-to-consumer television advertisement means an advertisement for a prescription drug product (as defined in section 735(3)) intended to be displayed on any television channel for less than 3 minutes. (5) The term DTC advertisement has the meaning indicated for such term in subsection (a)(1)(a). (6) The term operating reserve fee has the meaning indicated for such term in subsection (a)(2)(a). (7) The term person includes an individual, partnership, corporation, and association, and any affiliate thereof or successor in interest. (8) The term process for the advisory review of prescription drug advertising means the activities necessary to review and provide advisory comments on DTC advertisements prior to public dissemination and, to the extent the Secretary has additional staff resources available under the program under this section that are not necessary for the advisory review of DTC advertisements, the activities necessary to review and provide advisory comments on other proposed advertisements and promotional material prior to public dissemination. (9) The term resources allocated for the process for the advisory review of prescription drug advertising means the expenses incurred in connection with the process for the advisory review of prescription drug advertising for (A) officers and employees of the Food and Drug Administration, contractors of the Food and Drug Administration, advisory committees, and costs related to such officers, employees, and committees, and to contracts with such contractors; (B) management of information, and the acquisition, maintenance, and repair of computer resources; (C) leasing, maintenance, renovation, and repair of facilities and acquisition, maintenance, and repair of fixtures, furniture, scientific equipment, and other necessary materials and supplies; VerDate Aug :49 Oct 12, 2007 Jkt PO Frm Fmt 6580 Sfmt 6581 E:\PUBLAW\PUBL APPS24 PsN: PUBL085
18 121 STAT. 840 PUBLIC LAW SEPT. 27, USC 379h 2. Website. (D) collection of fees under this section and accounting for resources allocated for the advisory review of prescription drug advertising; and (E) terminating the program under this section pursuant to subsection (f)(2) if that becomes necessary. (10) The term resubmission means a subsequent submission for advisory review of a direct-to-consumer television advertisement that has been revised in response to the Secretary s comments on an original submission. A resubmission may not introduce significant new concepts or creative themes into the television advertisement. (11) The term submission for advisory review means an original submission of a direct-to-consumer television advertisement for which the sponsor voluntarily requests advisory comments before the advertisement is publicly disseminated.. SEC REAUTHORIZATION; REPORTING REQUIREMENTS. Part 2 of subchapter C of chapter VII (21 U.S.C. 379g et seq.), as amended by section 104, is further amended by inserting after section 736A the following: SEC. 736B. REAUTHORIZATION; REPORTING REQUIREMENTS. (a) PERFORMANCE REPORT. Beginning with fiscal year 2008, not later than 120 days after the end of each fiscal year for which fees are collected under this part, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report concerning the progress of the Food and Drug Administration in achieving the goals identified in the letters described in section 101(c) of the Food and Drug Administration Amendments Act of 2007 during such fiscal year and the future plans of the Food and Drug Administration for meeting the goals. The report for a fiscal year shall include information on all previous cohorts for which the Secretary has not given a complete response on all human drug applications and supplements in the cohort. (b) FISCAL REPORT. Beginning with fiscal year 2008, not later than 120 days after the end of each fiscal year for which fees are collected under this part, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on the implementation of the authority for such fees during such fiscal year and the use, by the Food and Drug Administration, of the fees collected for such fiscal year. (c) PUBLIC AVAILABILITY. The Secretary shall make the reports required under subsections (a) and (b) available to the public on the Internet Web site of the Food and Drug Administration. (d) REAUTHORIZATION. (1) CONSULTATION. In developing recommendations to present to the Congress with respect to the goals, and plans for meeting the goals, for the process for the review of human drug applications for the first 5 fiscal years after fiscal year 2012, and for the reauthorization of this part for such fiscal years, the Secretary shall consult with (A) the Committee on Energy and Commerce of the House of Representatives; VerDate Aug :45 Oct 12, 2007 Jkt PO Frm Fmt 6580 Sfmt 6581 E:\PUBLAW\PUBL APPS24 PsN: PUBL085
19 PUBLIC LAW SEPT. 27, STAT. 841 (B) the Committee on Health, Education, Labor, and Pensions of the Senate; (C) scientific and academic experts; (D) health care professionals; (E) representatives of patient and consumer advocacy groups; and (F) the regulated industry. (2) PRIOR PUBLIC INPUT. Prior to beginning negotiations with the regulated industry on the reauthorization of this part, the Secretary shall (A) publish a notice in the Federal Register requesting public input on the reauthorization; (B) hold a public meeting at which the public may present its views on the reauthorization, including specific suggestions for changes to the goals referred to in subsection (a); (C) provide a period of 30 days after the public meeting to obtain written comments from the public suggesting changes to this part; and (D) publish the comments on the Food and Drug Administration s Internet Web site. (3) PERIODIC CONSULTATION. Not less frequently than once every month during negotiations with the regulated industry, the Secretary shall hold discussions with representatives of patient and consumer advocacy groups to continue discussions of their views on the reauthorization and their suggestions for changes to this part as expressed under paragraph (2). (4) PUBLIC REVIEW OF RECOMMENDATIONS. After negotiations with the regulated industry, the Secretary shall (A) present the recommendations developed under paragraph (1) to the Congressional committees specified in such paragraph; (B) publish such recommendations in the Federal Register; (C) provide for a period of 30 days for the public to provide written comments on such recommendations; (D) hold a meeting at which the public may present its views on such recommendations; and (E) after consideration of such public views and comments, revise such recommendations as necessary. (5) TRANSMITTAL OF RECOMMENDATIONS. Not later than January 15, 2012, the Secretary shall transmit to the Congress the revised recommendations under paragraph (4), a summary of the views and comments received under such paragraph, and any changes made to the recommendations in response to such views and comments. (6) MINUTES OF NEGOTIATION MEETINGS. (A) PUBLIC AVAILABILITY. Before presenting the recommendations developed under paragraphs (1) through (5) to the Congress, the Secretary shall make publicly available, on the public Web site of the Food and Drug Administration, minutes of all negotiation meetings conducted under this subsection between the Food and Drug Administration and the regulated industry. (B) CONTENT. The minutes described under subparagraph (A) shall summarize any substantive proposal made Federal Register, publication. Website. Federal Register, publication. Website. VerDate Aug :49 Oct 12, 2007 Jkt PO Frm Fmt 6580 Sfmt 6581 E:\PUBLAW\PUBL APPS24 PsN: PUBL085
20 121 STAT. 842 PUBLIC LAW SEPT. 27, USC 379g note. 21 USC 379h USC 379g note. 21 USC 379g note. Medical Device User Fee Amendments of USC 301 note. 21 USC 379i note. by any party to the negotiations as well as significant controversies or differences of opinion during the negotiations and their resolution.. SEC SUNSET DATES. (a) AUTHORIZATION. The amendments made by sections 102, 103, and 104 cease to be effective October 1, (b) REPORTING REQUIREMENTS. The amendment made by section 105 ceases to be effective January 31, SEC EFFECTIVE DATE. The amendments made by this title shall take effect on October 1, 2007, or the date of the enactment of this Act, whichever is later, except that fees under part 2 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act shall be assessed for all human drug applications received on or after October 1, 2007, regardless of the date of the enactment of this Act. SEC SAVINGS CLAUSE. Notwithstanding section 509 of the Prescription Drug User Fee Amendments of 2002 (21 U.S.C. 379g note), and notwithstanding the amendments made by this title, part 2 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act, as in effect on the day before the date of the enactment of this title, shall continue to be in effect with respect to human drug applications and supplements (as defined in such part as of such day) that on or after October 1, 2002, but before October 1, 2007, were accepted by the Food and Drug Administration for filing with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year SEC TECHNICAL AMENDMENT; CONFORMING AMENDMENT. (a) Section 739 (21 U.S.C. 379j 11) is amended in the matter preceding paragraph (1) by striking subchapter and inserting part. (b) Paragraph (11) of section 739 (21 U.S.C. 379j 11) is amended by striking 735(9) and inserting 735(11). TITLE II MEDICAL DEVICE USER FEE AMENDMENTS OF 2007 SEC SHORT TITLE; REFERENCES IN TITLE; FINDING. (a) SHORT TITLE. This title may be cited as the Medical Device User Fee Amendments of (b) REFERENCES IN TITLE. Except as otherwise specified, amendments made by this title to a section or other provision of law are amendments to such section or other provision of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.). (c) FINDING. The Congress finds that the fees authorized under the amendments made by this title will be dedicated toward expediting the process for the review of device applications and for assuring the safety and effectiveness of devices, as set forth in the goals identified for purposes of part 3 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate and the Chairman of the Committee on Energy VerDate Aug :49 Oct 12, 2007 Jkt PO Frm Fmt 6580 Sfmt 6581 E:\PUBLAW\PUBL APPS24 PsN: PUBL085